Moscow- Russia has announced that its newly developed cancer vaccine has delivered promising results in three years of preclinical trials and is now awaiting approval for clinical use.

Veronika Skvortsova, head of the Federal Medical-Biological Agency, said the vaccine proved both safe and highly effective, with trials showing tumor reduction, slower growth, and survival improvements. In some cancer types, effectiveness reached 60–80%.

Documents have been submitted to the Health Ministry, with the first rollout expected for colorectal cancer, followed by glioblastoma and melanoma.

Developed by the Gamaleya Research Institute, the mRNA-based vaccine uses artificial intelligence to train the immune system to target cancer cells. The institute, which also created the Sputnik V Covid-19 vaccine, is applying similar technology to develop an HIV vaccine.